ATE230020T1 - Katalytische antikörperkomponente - Google Patents

Katalytische antikörperkomponente

Info

Publication number
ATE230020T1
ATE230020T1 AT91907066T AT91907066T ATE230020T1 AT E230020 T1 ATE230020 T1 AT E230020T1 AT 91907066 T AT91907066 T AT 91907066T AT 91907066 T AT91907066 T AT 91907066T AT E230020 T1 ATE230020 T1 AT E230020T1
Authority
AT
Austria
Prior art keywords
catalytic
catalytic antibody
antibody components
disclosed
methods
Prior art date
Application number
AT91907066T
Other languages
English (en)
Inventor
Sudhir Paul
Michael J Powell
Richard J Massey
John H Kenten
Original Assignee
Igen Int Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Igen Int Inc filed Critical Igen Int Inc
Application granted granted Critical
Publication of ATE230020T1 publication Critical patent/ATE230020T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/57563—Vasoactive intestinal peptide [VIP]; Related peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • C07K14/55—IL-2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/06—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies from serum
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/26—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against hormones ; against hormone releasing or inhibiting factors
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/44—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material not provided for elsewhere, e.g. haptens, metals, DNA, RNA, amino acids
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/0002—Antibodies with enzymatic activity, e.g. abzymes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/70—Fusion polypeptide containing domain for protein-protein interaction
    • C07K2319/74—Fusion polypeptide containing domain for protein-protein interaction containing a fusion for binding to a cell surface receptor
    • C07K2319/75—Fusion polypeptide containing domain for protein-protein interaction containing a fusion for binding to a cell surface receptor containing a fusion for activation of a cell surface receptor, e.g. thrombopoeitin, NPY and other peptide hormones

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Zoology (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Wood Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Endocrinology (AREA)
  • Vascular Medicine (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Enzymes And Modification Thereof (AREA)
AT91907066T 1990-03-23 1991-03-22 Katalytische antikörperkomponente ATE230020T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US07/498,225 US5229272A (en) 1989-04-25 1990-03-23 Catalytic antibody components
PCT/US1991/001948 WO1991014769A1 (en) 1990-03-23 1991-03-22 Catalytic antibody components

Publications (1)

Publication Number Publication Date
ATE230020T1 true ATE230020T1 (de) 2003-01-15

Family

ID=23980122

Family Applications (1)

Application Number Title Priority Date Filing Date
AT91907066T ATE230020T1 (de) 1990-03-23 1991-03-22 Katalytische antikörperkomponente

Country Status (11)

Country Link
US (1) US5229272A (de)
EP (1) EP0521996B1 (de)
JP (1) JPH05508073A (de)
KR (1) KR100244677B1 (de)
AT (1) ATE230020T1 (de)
AU (1) AU643776B2 (de)
CA (1) CA2038911A1 (de)
DE (1) DE69133179T2 (de)
IL (1) IL97653A (de)
WO (1) WO1991014769A1 (de)
ZA (1) ZA912036B (de)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5314642A (en) * 1984-11-27 1994-05-24 Igen, Inc. Interaction system comprising a surfactant-stabilized aqueous phase containing an antibody fragment
US5318897A (en) * 1989-04-25 1994-06-07 Igen, Inc. Monoclonal antibody and antibody components elicited to a polypeptide antigen ground state
US6291159B1 (en) * 1989-05-16 2001-09-18 Scripps Research Institute Method for producing polymers having a preselected activity
US6291161B1 (en) * 1989-05-16 2001-09-18 Scripps Research Institute Method for tapping the immunological repertiore
US6680192B1 (en) 1989-05-16 2004-01-20 Scripps Research Institute Method for producing polymers having a preselected activity
US6291158B1 (en) * 1989-05-16 2001-09-18 Scripps Research Institute Method for tapping the immunological repertoire
US6969586B1 (en) * 1989-05-16 2005-11-29 Scripps Research Institute Method for tapping the immunological repertoire
AU656181B2 (en) * 1991-05-03 1995-01-27 Pasteur Sanofi Diagnostics Heterobifunctional antibodies possessing dual catalytic and specific antigen binding properties and methods using them
US5302707A (en) * 1992-03-26 1994-04-12 Affymax Technologies N.V. 5-fluorouridine nucleoside phosphate compounds
US6765087B1 (en) * 1992-08-21 2004-07-20 Vrije Universiteit Brussel Immunoglobulins devoid of light chains
US6852507B1 (en) * 1994-01-31 2005-02-08 L'institut National De La Recherche Agronomique Recombinant baculovirus and use thereof in the production of monoclonal antibodies
US5844102A (en) * 1994-07-07 1998-12-01 University Of Maryland Baltimore County Glycohydrolase inhibitors, their preparation and use thereof
US6156541A (en) * 1995-07-21 2000-12-05 The Board Of Regents Of The University Of Nebraska Compositions and methods for catalyzing hydrolysis of HIV gp120
US5801064A (en) * 1995-12-04 1998-09-01 Foresman; Mark D. Assay methods and reagents for detecting autoantibodies
US5993549A (en) * 1996-01-19 1999-11-30 Deutsche Forschungsanstalt Fuer Luft- Und Raumfahrt E.V. Powder coating apparatus
AU1952497A (en) * 1996-02-13 1997-09-02 Regents Of The University Of California, The Novel antibody-cytokine fusion protein, and methods of making and using the same
ATE550042T1 (de) * 1997-11-20 2012-04-15 Vical Inc Behandlung von krebs mithilfe cytokin- exprimierender polynukleotide und zusammensetzungen dafür
US20030039659A1 (en) * 1999-09-24 2003-02-27 Mccormick Alison A. Self antigen vaccines for treating B cell lymphomas and other cancers
US7084256B2 (en) * 1999-09-24 2006-08-01 Large Scale Biology Corporation Self antigen vaccines for treating B cell lymphomas and other cancers
GB0907551D0 (en) 2009-05-01 2009-06-10 Univ Dundee Treatment or prophylaxis of proliferative conditions
EP2825553B1 (de) 2012-03-14 2018-07-25 Regeneron Pharmaceuticals, Inc. Multispezifische antigenbindungsmoleküle und verwendungen davon
JP6488520B2 (ja) * 2013-08-20 2019-03-27 国立研究開発法人科学技術振興機構 ヒト抗体κ型軽鎖複合体含有組成物及びその製造方法
IL296285A (en) 2015-07-06 2022-11-01 Regeneron Pharma Multispecific antigen-binding molecules and uses thereof
EP3448891A1 (de) 2016-04-28 2019-03-06 Regeneron Pharmaceuticals, Inc. Verfahren zur herstellung multispezifischer antigenbindender moleküle
DK3635009T3 (da) 2017-06-07 2026-03-30 Regeneron Pharma Sammensætninger og fremgangsmåder til internalisering af enzymer
AU2019216531A1 (en) 2018-02-02 2020-09-24 Maverix Oncology, Inc. Small molecule drug conjugates of gemcitabine monophosphate
US12258597B2 (en) 2018-02-07 2025-03-25 Regeneron Pharmaceuticals, Inc. Methods and compositions for therapeutic protein delivery
KR102871690B1 (ko) 2018-04-30 2025-10-16 리제너론 파마슈티칼스 인코포레이티드 Her2 및/또는 aplp2에 결합하는 항체 및 이중특이적 항원-결합 분자 및 접합체 그리고 이들의 용도
BR112020023145A2 (pt) 2018-05-17 2021-02-02 Regeneron Pharmaceuticals, Inc. anticorpo anti-cd63 ou fragmento de ligação ao antígeno do mesmo, molécula de ligação ao antígeno biespecífica, proteína terapêutica de múltiplos domínios, polinucleotídeo composição farmacêutica, e, composto

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4196265A (en) * 1977-06-15 1980-04-01 The Wistar Institute Method of producing antibodies
US4492751A (en) * 1978-04-10 1985-01-08 Miles Laboratories, Inc. Heterogenous specific binding assay employing an enzyme substrate as label
US4376110A (en) * 1980-08-04 1983-03-08 Hybritech, Incorporated Immunometric assays using monoclonal antibodies
US4493890A (en) * 1981-03-23 1985-01-15 Miles Laboratories, Inc. Activated apoglucose oxidase and its use in specific binding assays
US4661586A (en) * 1981-11-17 1987-04-28 The Board Of Trustees Of The Leland Stanford Junior University Monoclonal anti-idiotype antibodies
US4816567A (en) * 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
AU3745285A (en) * 1983-11-29 1985-06-13 Igen, Inc. Method of catalyzing chemical reactions
US5030717A (en) * 1986-09-17 1991-07-09 Scripps Clinic And Research Foundation Antibodies which catalyze hydrolysis of ester bonds
US4659567A (en) * 1984-09-07 1987-04-21 Scripps Clinic & Research Foundation Molecules with antibody combining sites that bind to hydrolytic transition states
WO1986006742A1 (en) * 1985-05-07 1986-11-20 California Biotechnology Inc. Fused proteine for enzyme immunoassay system
US4792446A (en) * 1986-06-23 1988-12-20 Igen, Inc. Production of antibody catalysts
US4963355A (en) * 1986-06-23 1990-10-16 Igen, Inc. Production of antibody catalysts
US4900674A (en) * 1987-05-28 1990-02-13 Scripps Clinic And Research Foundation Antibody combining sites that exhibit amide or ester synthase activity
AU2635088A (en) * 1987-12-04 1989-06-08 Du Pont Merck Pharmaceutical Company, The Immobilized interleukin 2 and interleukin 2 containing a carboxyl-terminal extension
ZA893284B (en) * 1988-05-04 1990-03-28 Igen Inc Peptide analogs and their use as haptens to elicit catalytic antibodies
EP0368684B2 (de) * 1988-11-11 2004-09-29 Medical Research Council Klonierung von Immunglobulin sequenzen aus den variabelen Domänen.
US5215889A (en) * 1988-11-18 1993-06-01 The Regents Of The University Of California Catalytic and reactive polypeptides and methods for their preparation and use
WO1990008185A1 (en) * 1989-01-17 1990-07-26 Scripps Clinic And Research Foundation Molecules with antibody combining sites that exhibit stereospecific catalysis
US5236836A (en) * 1989-04-25 1993-08-17 Igen, Inc. Autoantibodies which enhance the rate of a chemical reaction

Also Published As

Publication number Publication date
AU7559291A (en) 1991-10-21
US5229272A (en) 1993-07-20
IL97653A (en) 1998-01-04
EP0521996B1 (de) 2002-12-18
KR100244677B1 (ko) 2000-02-15
EP0521996A4 (en) 1993-06-30
EP0521996A1 (de) 1993-01-13
ZA912036B (en) 1991-12-24
JPH05508073A (ja) 1993-11-18
AU643776B2 (en) 1993-11-25
DE69133179T2 (de) 2003-11-13
IL97653A0 (en) 1992-06-21
DE69133179D1 (de) 2003-01-30
WO1991014769A1 (en) 1991-10-03
CA2038911A1 (en) 1991-09-24

Similar Documents

Publication Publication Date Title
DE69133179D1 (de) Katalytische antikörperkomponente
MX9603080A (es) Anticuerpos monoclonales inmuno-estimulantes.
ATE384792T1 (de) Antikörpervarianten mit höheren bindungsaffinitäten im vergleich zu parentalen antikörpern
ATE504601T1 (de) Anti-cd3-antikörper zur verwendung zur induzierung von immunsuppression
ATE346858T1 (de) Antikörperreinigung durch hydrophobe wechselwirkungchromatografie bei niedrigem ph
ATE200679T1 (de) Neues verfahren zur herstellung von anti-humanen antigenrezeptoren und deren verwendungen
BR9809656A (pt) Composição imunopotencializante
ATE166883T1 (de) Monoklonale antikörper (mak) gegen tumorassoziierte antigene, ihre herstellung und verwendung
PT856520E (pt) Metodo de preparacao de um anticorpo monoclonal, anticorpo monoclonal, uma composicao farmaceutica e um reagente de diagnostico
DK407987D0 (da) Apolipoprotein b-specifikke monoklonale antistoffer og hybridomer, som producerer disse antistoffer
DE3480494D1 (en) Method and reagent for use in the assay of pivka-ii
ID20117A (id) Antibodi anti-fas
WO1999024835A3 (en) An immunoassay for procollagen-iii-c-terminal propeptide
DE3850993D1 (de) Monoklonaler Antikörper spezifisch gegen humane Pankreas-Phospholipase-A2.
DK329789A (da) Monoklonalt antistof
ES2125011T3 (es) Procedimiento inmunologico de la antitrombina iii activada por un glicosaminoglicano, anticuerpos monoclonales correspondientes y su procedimiento de obtencion.
PT81050B (pt) Anticorpo monoclonal anti-urocinase e processo para a preparacao de composicoes de materia de teste biologicos que o utilizam
NO305867B1 (no) FremgangsmÕte til fremstilling av et monoklonalt antistoff mot Onkostatin M, eller et fragment derav
ATE125306T1 (de) Monoklonale antikörper, die einen unterschied zwischen nativproteinen und proteinen mit einer modifizierten sequenz machen.
IT8821547A0 (it) Metodo immunologico per la determinazione di anticorpi anti antigeni di microorganismi, mediante anticorpi antiidiotipo e mezzi adatti allo scopo.
KR950031110A (ko) 인간 혈증 아포지단백질 비-100(b-100)에 대한 신규 단일클론 항체 및 이들의 생산을 위한 재조합 하이브리도마 세포주
FI956041L (fi) Kompositiot ja diagnostiset menetelmät, joissa käytetään monoklonaalisia vasta-aineita CD44V6 vastaan
ECSP951605A (es) Fragmentos de anticuerpos monoclonales que tienen actividad inmunosupresora, case ran 4105/171
FI875475A7 (fi) Hiiren hybridoma Lym-1 ja sillä tuotettu diagnostinen vasta-aine.

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 0521996

Country of ref document: EP

REN Ceased due to non-payment of the annual fee